Cibc Private Wealth Group, LLC Alaunos Therapeutics, Inc. Transaction History

Cibc Private Wealth Group, LLC

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$0.04 - $0.13 $16 - $52	-400 Reduced 0.79%	50,000 $3,000
Q1 2023 May 11, 2023	BUY	$0.46 - $0.81 $9,200 - $16,200	20,000 Added 65.79%	50,400 $31,000
Q4 2022 Jun 01, 2023	SELL	$0.5 - $261.0 $10,000 - $5.22 Million	-20,000 Reduced 39.68%	30,400 $19,000
Q3 2022 Nov 14, 2022	SELL	$1.04 - $322.5 $11,533 - $3.58 Million	-11,090 Reduced 26.73%	30,400 $52,000
Q4 2021 Feb 08, 2022	BUY	$1.09 - $1.89 $218 - $378	200 Added 0.48%	41,490 $45,000
Q3 2021 Nov 12, 2021	BUY	$1.44 - $2.73 $612 - $1,160	425 Added 1.04%	41,290 $75,000
Q1 2021 May 12, 2021	SELL	$2.82 - $5.6 $2,932 - $5,824	-1,040 Reduced 2.48%	40,865 $147,000
Q4 2020 Feb 12, 2021	BUY	$2.09 - $3.09 $40,232 - $59,482	19,250 Added 84.97%	41,905 $106,000
Q3 2020 Nov 03, 2020	BUY	$2.39 - $3.43 $54,145 - $77,706	22,655 New	22,655 $57,000
Q3 2018 Nov 14, 2018	SELL	$2.26 - $3.27 $3,853 - $5,575	-1,705 Closed	0 $0
Q2 2018 Aug 02, 2018	SELL	$3.02 - $4.94 $54,767 - $89,586	-18,135 Reduced 91.41%	1,705 $5,000
Q1 2018 May 17, 2018	BUY	$3.46 - $5.14 $3,460 - $5,140	1,000 Added 5.31%	19,840 $78,000
Q4 2017 Feb 12, 2018	BUY	$4.0 - $6.54 $75,360 - $123,213	18,840	18,840 $78,000

92.6K

Ticker TCRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,182,000
Market Cap $458M
Description
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...

Get notified when there are updates to the investment portfolio of Cibc Private Wealth Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Cibc Private Wealth Group, LLC with notifications on news.